Author: acn

HONG KONG, Mar 16, 2026 - (ACN Newswire via SeaPRwire.com) – FWD Group Holdings Limited (“FWD Group” or “FWD”) today announced its first set of full-year results as a Hong Kong listed company for the 12 months ended 31 December 2025.- New business sales were up 25 per cent to US$2.446 billion compared to 2024 on an annualised premium equivalent (APE) basis. New business contractual service margin (CSM) was US$1.476 billion, with year-on-year growth of 18 per cent.- Operating profit after tax was up five per cent to US$499 million with positive contributions from each of the company’s four geographic reporting segments – Hong Kong SAR & Macau SAR; Thailand & Cambodia; Japan; and Emerging Markets.- Net profit of US$166 million is a record IFRS 17 result and for the second consecutive year, FWD Group was operating cash flow positive as at 31 December 2025. Leverage ratio reduced to 21.3 per cent approaching the company’s target range of 15-20 per cent.- Significantly increased important indicators of shareholder value creation, with comprehensive tangible equity (CTE) up 18 per cent to US$8.72 billion compared to 31 December 2024 and Group embedded value (EV) up 19 per cent year-on-year to US$6.85 billion. A strong capital position was maintained with a 265 per cent solvency ratio^.- In December 2025, FWD Group was added to the Hang Seng Composite Index and the eligible securities list for the Stock Connect programme, where Mainland Chinese investors connect via the Shanghai Stock Exchange and Shenzhen Stock Exchange with Hong Kong market opportunities via a southbound trading mechanism. FWD Group was also included in the MSCI Hong Kong Small Cap Index in February 2026.Huynh Thanh Phong, Group Chief Executive Officer and Executive Director of FWD Group, said, “2025 was a stand-out year for FWD Group. We successfully executed our customer-led strategy, underpinned by our digitally enabled business model. Record financial results were achieved. And of course, we began trading as a publicly listed company, following our July 2025 initial public offering. This fulfilled a long-held objective to ensure FWD Group has full capital market access, as a solid foundation for our future development and growth.”The strong 2025 results were driven by organic growth across most of the 10 Asian markets where FWD Group operates, with a particularly outstanding performance in the Hong Kong SAR & Macau SAR segment.A solid performance was posted in Japan, in a year where FWD began to diversify beyond its successful protection business into the retirement and savings segment, with its first offering – a yen-denominated single premium variable annuity product.As an established market leader in Thailand, FWD remains well positioned to grow quality new business in future, despite headwinds from a lower rate environment which impacted 2025 results, in addition to the 2024 exit from underwriting new business in the corporate care segment.Excellent growth was delivered in the Emerging Markets segment – which is comprised of five of the rest of FWD Group’s Southeast Asian markets – consistent with the longer-term demographic, wealth creation, and digital adoption trends in this region.“With 2026 already underway, we remain firmly focused on executing our strategy as we build for the future – operating with customers at the heart of everything we do in high-growth Asian markets, with a focus on long-term sustainability and profitability,” added Huynh Thanh Phong.About FWD GroupFWD Group (1828.HK) is a pan-Asian life and health insurance business that serves more than 38 million customers across 10 markets, including BRI Life in Indonesia. FWD’s customer-led and tech-enabled approach aims to deliver innovative propositions, easy-to-understand products and a simpler insurance experience. Established in 2013, the company operates in some of the fastest-growing insurance markets in the world with a vision of changing the way people feel about insurance. FWD Group is listed on the main board of the Hong Kong Stock Exchange under the stock code 1828.For more information, please visit www.fwd.comFor media inquiries, please contact: groupcommunications@fwd.comSource: FWD Group Holdings LimitedThe results are for the 12 months ended 31 December 2025 and are compared to the same period in 2024.Group LCSM cover ratio, group embedded value, comprehensive tangible equity values are December 2025 balances/ratios and growth rates are represented accordingly.Growth rates are represented on a constant exchange rate (CER) basis, unless otherwise stated.Except for operating profit/(loss) after tax (non-IFRS measure), net profit/(loss), and comprehensive tangible equity, all other numbers are unaudited. Operating profit after tax and net profit after tax represent the amounts attributable to equity holders of the company and are presented net of non-controlling interests. New business sales are calculated on an annualised premium equivalent (APE) basis, based on 100 percent annualised first year premiums and 10 percent single premiums. Comprehensive tangible equity is calculated as total equity of the Group attributable to shareholders of the Company plus contractual service margin (net of tax and non-controlling interests), minus intangible assets (net of non-controlling interests).* Actual exchange rate basis ^ Prescribed capital requirement (PCR) basis Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Santo Domingo, Dominican Republic, Mar 14, 2026 - (ACN Newswire via SeaPRwire.com) - In a strategic move to tap into the booming global short-drama market, AdsDrama LTD, an international digital content marketing company registered in Denver with $50 million in capital, has officially launched its tailored short-drama marketing ecosystem in the Dominican Republic. This event marks the company’s key step in expanding its global footprint, aiming to bridge the local content supply gap and build a sustainable digital entertainment model that combines its core strengths in advertising technology and community-driven growth.Short dramas — dozens of 1–3 minute episodes with fast-paced, emotional storytelling—are booming globally, fitting today's fragmented viewing habits. AdsDrama LTD, an international digital content marketing firm, is building a short-drama marketing ecosystem in the Dominican Republic, combining ad technology and community-driven strategies for sustainability.Short Dramas: The Next Digital Entertainment Growth EngineGlobal entertainment has shifted from long-form to short-form content, with short dramas offering advantages: 1–3 minute episodes, engaging storylines, mobile optimization, and higher monetization. The "free viewing + paid unlocking" model effectively retains audiences and generates revenue, fostering a full ecosystem of production, marketing, and commercialization.AdsDrama: Focused on Short-Drama MarketingRegistered in Denver with $50 million capital, AdsDrama's mission is a global short-drama marketing ecosystem integrating ad technology, distribution, data-driven strategies, and community promotion. Its core businesses include short-drama marketing, ad services, commercial operations, custom production, and IP incubation. Operating via "global technology + local operations," it adapts global expertise to local markets.Digital Advertising: The Growth EngineEffective distribution is key for short dramas. AdsDrama promotes content across social media, short-video platforms, portals, and search channels, optimizing campaigns via data analytics. Revenue streams include advertising, paid content, brand partnerships, and IP commercialization—forming the industry's financial foundation.Community-Driven "Co-Builder" ModelAdsDrama's "co-builder ecosystem" invites local participants to share content, provide market feedback, and expand reach. In return, co-builders get marketing materials, data access, and training—leveraging community trust, which outweighs algorithmic traffic in Latin America.User Experience & VIP StructureNew users get a free trial (RD$25–RD$60) to learn the platform's workflow and revenue model. For deep engagement, VIP levels (e.g., VIP3: RD$16,200 participation, daily returns of RD$270–RD$648 for 730 days) offer tiered benefits, with automatic revenue calculation and principal return options post-cooperation.Why the Dominican Republic?The country is a key market due to its young population (high digital entertainment demand), widespread mobile internet usage, and a gap in professionally produced short dramas—creating ideal conditions for ecosystem development.Three-Phase Development StrategyAdsDrama's 3-year plan: Phase 1 (1–6 months): Launch flagship dramas, build user communities, optimize marketing; Phase 2 (7–18 months): Expand promotion, improve operations, diversify revenue; Phase 3 (19–36 months): Open to independent creators, build a comprehensive ecosystem, and expand to the Caribbean and Latin America.The Future of the Digital Content EcosystemAs mobile internet continues to evolve, the digital entertainment industry is undergoing constant transformation.Short videos changed how audiences consume media. Short dramas may represent the next stage of this evolution - combining storytelling, advertising, and digital commerce in a single content format.Companies like AdsDrama LTD believe that the future of digital content will rely on the integration of multiple elements:creative storytellingtechnology infrastructuredata-driven marketingcommunity-based promotionIn this ecosystem:creators focus on producing contentplatforms provide technology and marketing toolscommunities help amplify distributionTogether, these elements form a sustainable and scalable digital content economy.Short dramas represent the next evolution of digital entertainment, integrating storytelling, advertising, and commerce. AdsDrama's focus on infrastructure, community, and data will drive the industry's growth, with the Dominican Republic and Latin America at the forefront of this transformation.Media contactBrand: AdsDrama LTDContact: Media teamWebsite: https://www.adsdrama.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

MIAMI, FL, Mar 13, 2026 - (ACN Newswire via SeaPRwire.com) - General MRO Aerospace (GMA) today announced that it has officially received certification from the Civil Aviation Administration of China (CAAC), authorizing the company to perform maintenance, repair, and overhaul (MRO) services for components on Chinese-registered aircraft.The certification marks a significant milestone in General MRO Aerospace's international growth strategy and further validates the company's commitment to the highest standards of safety, quality, and regulatory compliance."Achieving CAAC certification is an important step forward for General MRO Aerospace as we continue to expand our global footprint," said Jonathan Cornell, President of General MRO Aerospace. "This approval demonstrates the strength of our quality systems, our technical expertise, and our commitment to supporting Airline and MRO partners worldwide."The CAAC approval allows GMA to provide repair and overhaul services for a range of aircraft components in accordance with Chinese aviation regulatory requirements. The certification process included a comprehensive audit of the company's facilities, quality management system, technical procedures, and regulatory compliance programs.General MRO Aerospace already operates under FAA Part 145, EASA, CAA, and CAAT quality standards, and the addition of CAAC certification enables the company to better serve operators, lessors, and maintenance providers across the Asia-Pacific aviation market."With increasing global demand for high-quality component repair services, this certification strengthens our ability to support customers operating in China and throughout the region," Cornell added. "We look forward to building strong partnerships with Chinese airlines and aviation organizations."General MRO Aerospace specializes in the repair and overhaul of complex aircraft components, supporting commercial and cargo operators worldwide with reliable turnaround times, technical excellence, and customer-focused service.About General MRO AerospaceGeneral MRO Aerospace is an AS9110 and ISO 9001 accredited U.S.-based aviation maintenance, repair, and overhaul provider specializing in component repair and support services for commercial aircraft operators worldwide. Operating under FAA Part 145, EASA, CAA, CAAT, and CAAC certification, the company delivers high-quality technical solutions, responsive customer service, and dependable turnaround times to airlines, leasing companies, and MRO partners around the globe.Media ContactMichelle TorresMarketing SpecialistGeneral MRO AerospaceMtorres@GeneralMROAerospace.comwww.GeneralMROAerospace.comSOURCE: General MRO Aerospace Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

佛罗里达州迈阿密, 2026年3月13日 - (亚太商讯 via SeaPRwire.com) - General MRO Aerospace（GMA）今日宣布，已正式获得中国民用航空局（CAAC）的认证，授权该公司为中国注册飞机的部件提供维护、修理和大修（MRO）服务。该认证标志着通用MRO航空公司在国际发展战略上的重要里程碑，进一步印证了公司对最高安全标准、质量标准及法规合规性的承诺。“获得中国民航局认证是通用MRO航空公司在持续拓展全球业务版图过程中的重要一步，”通用MRO航空公司总裁乔纳森·康奈尔表示。“此次批准彰显了我们质量管理体系的实力、技术专长，以及我们致力于支持全球航空公司和MRO合作伙伴的承诺。”凭借民航局（CAAC）的批准，GMA可根据中国航空监管要求，为各类飞机部件提供维修和大修服务。认证过程包括对公司设施、质量管理体系、技术程序及合规计划的全面审核。General MRO Aerospace 目前已按照美国联邦航空局（FAA）第 145 部、欧洲航空安全局（EASA）、英国民航局（CAA）及中国民航局（CAAT）的质量标准开展运营，此次新增的 CAAC 认证将使公司能够更好地服务于亚太航空市场中的运营商、租赁商及维修服务提供商。“随着全球对高质量部件维修服务需求的增长，此次认证增强了我们支持在中国及整个地区运营的客户的能力，”康奈尔补充道。“我们期待与中国航空公司及航空组织建立牢固的合作伙伴关系。”General MRO Aerospace 专注于复杂飞机部件的维修和大修，凭借可靠的周转时间、卓越的技术实力以及以客户为中心的服务，为全球的民航和货运运营商提供支持。关于 General MRO AerospaceGeneral MRO Aerospace 是一家总部位于美国、通过 AS9110 和 ISO 9001 认证的航空维修、检修与大修服务提供商，专注于为全球商用飞机运营商提供部件维修及支持服务。公司持有美国联邦航空局（FAA）第145部、欧洲航空安全局（EASA）、英国民航局（CAA）、加拿大航空运输局（CAAT）及中国民用航空局（CAAC）的认证，为全球航空公司、租赁公司及MRO合作伙伴提供高质量的技术解决方案、响应迅速的客户服务以及可靠的周转时间。媒体联系Michelle Torres市场营销专员General MRO Aerospace Mtorres@GeneralMROAerospace.comwww.GeneralMROAerospace.com 来源：General MRO Aerospace Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SHENZHEN, CHINA, Mar 13, 2026 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (“CMS”, or the “Group”) is pleased to announce that on 13 March 2026, new drug for renal anaemia Desidustat Tablets (the “Product”) has been approved for marketing in China by the National Medical Products Administration of the People’s Republic of China (NMPA). The Product is a novel, oral HypoxiaInducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in non-dialysis adult, Chronic Kidney Disease (CKD) patients.The approval of Desidustat Tablets will further strengthen the Group’s overall layout in the field of nephrology, and synergize with the marketed innovative drug Velphoro (Sucroferric Oxyhydroxide Chewable Tablets, indicated for CKD hyperphosphatemia). Through the efficient linkage of nephrology expert resources and channel networks, the Group is expected to rapidly promote the large-scale clinical application of Desidustat Tablets, providing differentiated treatment options for Chinese CKD patients with renal anaemia and making a positive contribution to the Group’s performance.More information about Desidustat Tablets and Renal AnaemiaAs a novel oral HIF-PHI, the Product’s mechanism of action promotes erythropoiesis through increasing endogenous erythropoietin, improving iron availability and reducing hepcidin. Its China Phase III clinical trial has demonstrated positive results. The primary endpoint of the haemoglobin (Hb) mean change from baseline to Week 7-9 has indicated that, Desidustat is more effective than placebo in increasing Hb level. Results from the extension study demonstrate that the Product can maintain Hb level within the target range over the long term with acceptable safety. In addition, the Product significantly reduces hepcidin levels and ameliorates iron metabolism disorders.There is still a large unmet need in the treatment of anaemia in CKD patients in China. It is estimated that there are more than 120 million CKD patients in China[1]. Anaemia is one of the frequent complications of CKD, which exhibits a progressively increasing incidence with disease progression. A survey in China showed that the prevalences of anaemia in patients at CKD stage 1 to 5 were 22.0%, 37.0%, 45.4%, 85.1%, and 98.2%, respectively[2]. The target-achieving rate (the Hb level reaching the target value (110~120g / L)) has increased to 51.5% for haemodialysis CKD patients with anaemia[3], but is still only 8.2% for anaemia patients in non-dialysis CKD[4]. The Product is administrated orally, thus expecting to improve the treatment compliance of patients and to meet the unmet treatment needs in the field of CKD anaemia.Desidustat Tablets have been approved for marketing in India.CMS INTERNATIONAL DEVELOPMENT AND MANAGEMENT LIMITED, a wholly-owned subsidiary of the Group, obtained an exclusive license for the Product from Zydus Lifesciences Limited (earlier known as Cadila Healthcare Limited) pursuant to a License Agreement with an effective date of 20 January 2020.The Group adheres to its core strategy of “innovation-driven”, having established a tiered and multi-dimensional innovation product portfolio with abundant reserves: 7 new drugs have been approved for marketing, 6 are currently under marketing review, and nearly 20 projects are about to initiate or are progressing through clinical trials. Through a dual-engine innovation approach combining collaborative development and in-house R&D, the Group continuously enriches its innovative pipeline centered on first-in-class (FIC) and best-in-class (BIC) products, efficiently advancing clinical development and commercialization. Moving forward, CMS will remain clinical needs-driven to deliver more quality pharmaceutical solutions, steadfastly advancing toward the goal of becoming a specialty-focused, innovation-excellent multinational pharmaceutical enterprise.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the Cardiovascular-Kidney-Metabolic/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.Reference1. ZhangL, WangF, WangL, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey[J]. Lancet, 2012, 379(9818):815-822. DOI: 10.1016/S0140-6736(12)60033-62. Chinese Expert Consensus on the Diagnosis and Treatment of Renal Anemia (2014 Revised Edition)[J]. Chinese Journal of Nephrology, 2014, 30(9): 712-716. DOI: 10.3760/cma.j.issn.1001-7097.2014.09.0153. 19th CSN Critical Care & Blood Purification Congress, Chinese Medical Association (July 2-5, 2025)4. Chinese Expert Consensus on the Diagnosis and Treatment of Renal Anemia (2018 Revised Edition)[J]. Chinese Journal of Nephrology, 2018, 34(11): 860-866. DOI: 10.3760/cma.j.issn.1001-7097.2018.11.012CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsWebsite: https://web.cms.net.cn/en/home/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 13, 2026 - (ACN Newswire via SeaPRwire.com) – CITIC Resources Holdings Limited (hereinafter referred to as CITIC Resources or the Company, or the Group when its subsidiaries are included; Stock Code: 1205.HK) has announced its annual results for the year ended 31 December 2025 (the “Year”). During the Year, the Group actively responded to the complex international environment and cyclical industry pressures. Systematically advancing initiatives in “upstream asset deployment, expansion of trading business, and enhancement of production and operations”, the Group deepened its dual-engine development model of “investment + trading”, stabilised its core operations, cultivated a second growth curve, and demonstrated robust operational and developmental resilience.As a key growth driver for the Group, the oil and gas trading business within the import and export segment expanded steadily during the Year, achieving a significant milestone with a trading volume exceeding 20.0 million barrels and revenue reaching approximately HK$11.34 billion. Meanwhile, the Group broke the long-standing monopoly of the sales channel of crude oil, enhancing the market value of its oil and gas properties. In the non-oil-and-gas business, the Group consistently prioritises refined and proactive management of its equity investments as a core task and actively conveyed its philosophy of improving quality and enhancing efficiency to the operators. Notably, the value of shares held in Aloca Corporation (“Aloca”) increased by approximately 46.3% during the Year. On the oil and gas front, focusing on refined reservoir management and continuous scientific research breakthroughs, the Group achieved stable production and increased reserves. It comprehensively deepened lean management throughout the production process, coupled with the implementation of cost-reduction and efficiency-enhancement measures, propelled continuous improvements in management standards and operational efficiency across all phases of oil and gas projects from exploration, development to production.During the Year, the Group achieved revenue of approximately HK$14.96 billion (2024: approximately HK$9.50 billion), representing a year-on-year increase of approximately 57.6%. Impacted by factors such as a decline in the average selling price of crude oil and coal, and higher raw material costs, profit attributable to ordinary shareholders of the Company amounted to approximately HK$0.17 billion (2024: HK$0.57 billion). Despite that, all of the Group’s segments recorded profits for the Year and the Group continued to maintain a strong financial position with cash and deposits of approximately HK$3.52 billion as at 31 December 2025 (31 December 2024: HK$2.03 billion). As at 31 December 2025, the Group had total assets of approximately HK$14.61 billion, and net assets attributable to ordinary shareholders of the Company of approximately HK$8.79 billion. The gearing ratio and interest-bearing debt ratio were approximately 38.8% and 23.5% respectively, with a return on equity (annualised) of approximately 2.0%.As part of its efforts to optimise its asset structure, the Group disposed of shares in Alcoa in January and March 2026, totalling approximately 2.17% of Alcoa’s total issued shares[1]. By seizing the opportunity to monetise its investment at a high valuation, the Group continues to create greater value for its shareholders.Mr. Hao Weibao, Executive Director, Chairman and Chief Executive Officer of CITIC Resources, said: “Looking ahead to 2026, the Group will focus on key areas such as the development, production and trading of oil and gas, as well as investments in the aluminum industry chain, deepen synergies among trading, investment and production management, and continue to implement the business strategy of consolidating the existing core business and pursuing dual-engine expansion through ‘investment + trading’.To consolidate our existing principal business, the Group will continue to enhance lean production and operational management to increase reserves and output, while steadily expanding production and sales scale. The Group will also intensify the introduction and application of new processes and technologies, leveraging technological innovation to empower high-quality development of our core businesses and reinforce our core growth foundation.On the dual-engine driver of ‘investment + trading’ expansion front, the Group will continue to track and position in high-quality oil and gas assets and the aluminium-centric key metals industry chain. Trading operations and investment projects will be deeply integrated: the investment arm will secure equity resources, while the trading arm will achieve market-oriented sales. This approach will also enhance our market sensitivity, enabling us to identify and acquire high-quality upstream resources and assets, thereby creating a virtuous cycle in which ‘investment acquires resources and trading converts value’. The Group is committed to implementing these development strategies and will continue to deliver long-term and stable returns to our shareholders.”[1]Details regarding the disposal were disclosed in the announcements and circular dated 16 January, 6 February, and 5 March.For details of CITIC Resources’ 2025 annual results, please refer to the Group’s annual results announcement on the Hong Kong Stock Exchange and the Group’s website.About CITIC Resources Holdings Limited (Stock Code: 1205.HK)CITIC Resources Holdings Limited has been listed on the Hong Kong Stock Exchange since 1997. Principal activities of CITIC Resources include the exploration, development and production of oil and coal, investments in bauxite mining, alumina refinery, aluminium smelting and oil and gas trading. CITIC Limited is the largest shareholder with about 59.5% interest in CITIC Resources. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月13日 - (亚太商讯 via SeaPRwire.com) - 中信资源控股有限公司（「中信资源」或「公司」，连同其附属公司统称为「集团」；股份代号：1205.HK）公布截至2025年12月31日止年度（「年内」）之全年业绩。年内集团积极应对复杂国际市场环境及行业周期性波动压力，系统推进「上游资产布局、贸易业务拓展、生产运营提质」工作，深化「投资+贸易」双轮驱动发展模式，稳固经营基本盘，培育第二增长曲线，彰显了强大的经营和发展韧性。作为集团主要的增长引擎之一，进出口业务板块中的油气贸易业务年内稳步拓展，贸易量超2,000万桶，实现贸易收入约113.4亿港元，达成重大里程碑。集团同时打破权益油销售多年被垄断局面，提升权益油市场价值。非油业务方面，集团始终将参股项目的精细化、主动化管理作为核心工作，向作业方传导提质增效理念，其中所持有的美国铝业公司（「美国铝业」）股份价值年内增长46.3%。油气业务方面，集团以精细化油藏管理与持续科研攻关为核心，实现稳产增储；全面深化生产过程的精益管理，落实降本增效举措，推动油气项目在勘探、开发及生产各环节的管理水平和运营效益持续提升。年内，集团实现营业收入约149.6亿港元（2024年：约95.0亿港元），同比增长约57.6%。受原油及煤炭的平均售价下降、原材料成本上升等因素影响，本公司普通股股东应占溢利约1.7亿港元（2024年：约5.7亿港元）。尽管如此，集团全部分类于本年度录得溢利，且于2025年12月31日继续维持稳健的财务状况，现金及存款约为35.2亿港元（2024年12月31日：20.3亿港元）。截至2025年12月31日，集团总资产146.1亿港元，归母净资产约87.9亿港元，资产负债率约38.8%，有息负债率约23.5%，净资产收益率约2.0%。作为优化资产结构的举措之一，集团于2026年1月及3月先后减持美国铝业股份，累计出售相当于其已发行股份总数约2.17%。集团精准把握高位变现的时机，持续为股东创造更大价值[1]。中信资源执行董事、主席兼行政总裁郝维宝先生表示：「展望2026年，集团将聚焦油气开发生产与贸易、铝产业链投资等关键领域，深化贸易、投资与生产运营协同，持续贯彻『夯实存量主业、「投资+贸易」双轮拓展』的经营策略。夯实存量主业方面，集团将持续深化精益生产运营管理，实现增储上产，稳步扩大产销规模；同时加大新工艺、新技术引进与应用力度，以科技创新赋能主业高质量发展，筑牢核心发展根基；『投资+贸易』双轮拓展方面，持续跟踪和布局优质油气资产及以铝为核心的关键金属产业链，贸易业务与投资项目形成深度联动，投资端获取权益资源，贸易端实现市场化销售，同时形成市场触角，识别并获取位于产业链上游的优质资源资产，形成『投资获取资源，贸易转化价值』的良性循环。集团将致力落实此等发展战略，持续为广大股东创造长期稳定的价值回报。」[1]出售事项的相关详情可见于1月16日、2月6日及3月5日刊出的公告及通函。有关中信资源2025年全年业绩的详情，请参考集团在香港联交所及其网站的全年业绩公告。关于中信资源控股有限公司（股份代号：1205.HK）中信资源控股有限公司自1997年起，在香港联合交易所上市。中信资源的主要业务包括石油和煤的勘探、开发和生产，于铝土矿开采、氧化铝冶炼和电解铝领域的投资及油气贸易。中国中信股份有限公司持有中信资源约59.5%的股权，为中信资源最大股东。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

深圳, 2026年3月13日 - (亚太商讯 via SeaPRwire.com) - 康哲药业控股有限公司(867.HK/8A8.SG)（"康哲药业"）欣然宣布，肾性贫血新药德昔度司他片（原名：德度司他片）（"产品"）上市许可申请已于2026年3月13日获得中国国家药品监督管理局（NMPA）批准。产品为一种创新型口服低氧诱导因子-脯氨酰羟化酶抑制剂（HIF-PHI），适用于非透析的成人慢性肾脏病（CKD）患者的贫血治疗。德昔度司他片获批上市，将进一步强化康哲药业在肾病专科领域的整体布局，并与处于商业化阶段的创新药维福瑞（蔗糖羟基氧化铁咀嚼片，用于CKD高磷血症）协同增效。通过肾内科专家资源与渠道网络的高效联动，康哲药业有望快速推动德昔度司他片的规模化临床应用，为中国CKD肾性贫血患者提供差异化的治疗选择，为集团业绩带来积极贡献。关于德昔度司他片和肾性贫血的更多信息作为一种创新型口服HIF-PHI，产品作用机制为通过增加内源性促红细胞生成素的生成、改善铁的利用率和降低铁调素的水平来促进红细胞生成。其中国III期临床试验取得了积极结果。主要研究终点血红蛋白（Hb）水平（第7-9周Hb平均值相对于基线的变化）结果显示，试验组优于安慰剂组。扩展期研究结果显示，产品可使Hb水平长期维持在达标水平，且安全性良好。此外，产品还可以显著降低铁调素水平，纠正铁代谢紊乱。中国CKD贫血治疗领域仍存在显著的未被满足需求。据估计，中国有超过1.2亿CKD患者[1]，贫血作为其常见并发症之一，发生率随病程进展呈逐步升高趋势。国内一项调研显示，CKD1～5 期患者贫血患病率依次为：22.0%、37.0%、45.4%、85.1%和98.2%[2]。血液透析CKD贫血患者的治疗达标率（Hb水平达到靶目标值（110～120 g/L））已提升至51.5%[3]，但对于非透析CKD贫血患者来说仍仅为8.2%[4]。产品采用口服给药，有望提高患者的治疗顺应性，有望满足CKD贫血领域未被满足的治疗需求。产品已在印度获批上市。康哲药业之全资附属公司康哲国际发展管理有限公司通过生效日为2020年1月20日的《许可协议》从Zydus Lifesciences Limited（前称为Cadila Healthcare Limited）处获得产品的独家许可权利。康哲药业坚持 "创新驱动" 核心战略，已构建起梯队衔接、储备充足的立体化创新产品矩阵：7款新药获批上市、6款正处于上市审评阶段、近20个项目即将开展/正在推进临床试验。康哲药业通过"合作开发+自主研发"双轮驱动创新，持续丰富以全球首创（FIC）、同类最优（BIC）产品为核心的创新管线，高效推进临床开发与商业化落地。未来，康哲药业将继续以临床需求为导向，提供更多优质医药解决方案，坚定向专科聚焦、创新卓越的国际化医药企业迈进。关于康哲药业康哲药业是一家链接医药创新与商业化，把控产品全生命周期管理的开放式平台型企业，致力于提供有竞争力的产品和服务，满足尚未满足的医疗需求。康哲药业专注于全球首创（FIC）及同类最优（BIC）的创新产品，并高效推进创新产品临床研究开发和商业化进程，赋能科研成果向诊疗实践的持续转化，造福患者。康哲药业聚焦专科领域，拥有被验证的商业化能力，广泛的渠道覆盖和多疾病领域专家资源，核心在售产品已获领先的学术与市场地位。康哲药业围绕优势专科领域不断纵深发展，以巩固心肾代谢/消化/眼科/皮肤健康业务竞争力，带来专科规模效率，其中皮肤健康业务（德镁医药）已成为其细分领域的龙头企业，并拟于联交所独立上市。同时，康哲药业持续推动研产销全产业链在东南亚及中东区域运营发展，以获取新兴市场的增量，助力集团实现高质量可持续发展。参考文献/资料1. ZhangL, WangF, WangL, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey[J]. Lancet, 2012, 379(9818):815-822. DOI: 10.1016/S0140-6736(12)60033-62. 肾性贫血诊断与治疗中国专家共识（2014修订版）[J]. 中华肾脏病杂志, 2014, 30(9): 712-716. DOI: 10.3760/cma.j.issn.1001-7097.2014.09.0153. 中华医学会肾脏病学分会第十九届重症肾脏病与血液净化大会（2025年7月2-5日）4. 肾性贫血诊断与治疗中国专家共识（2018修订版）[J]. 中华肾脏病杂志, 2018, 34(11): 860-866. DOI: 10.3760/cma.j.issn.1001-7097.2018.11.012康哲药业免责与前瞻性声明本新闻无意向您做任何产品的推广，非广告用途。本新闻不对任何药品和医疗器械和/或适应症作推荐。若您想了解具体疾病诊疗信息，请遵从医生或其他医疗卫生专业人士的意见或指导。医疗卫生专业人士作出的任何与治疗有关的决定应根据患者的具体情况并遵照药品说明书。由康哲药业编制的此新闻不构成购买或认购任何证券的任何要约或邀请，不形成任何合约或任何其他约束性承诺的依据或加以依赖。本新闻由康哲药业根据其认为可靠之资料及数据编制，但康哲药业并无进行任何说明或保证、明述或暗示，或其他表述，对本新闻内容的真实性、准确性、完整性、公平性及合理性不应加以依赖。本新闻中讨论的若干事宜可能包含涉及康哲药业的市场机会及业务前景的陈述，该等陈述分别或统称为前瞻性声明。该等前瞻性声明并非对未来表现的保证，存在已知及未知的风险、不明朗性及难以预知的假设。康哲药业并不采纳本新闻包含的第三方所做的任何前瞻性声明及预测，康哲药业对该等第三方声明及预测不承担责任。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 13, 2026 - (ACN Newswire via SeaPRwire.com) – uSmart Securities Limited ("uSMART Securities/the Company") is pleased to announce the official opening of its ninth and tenth physical service centres in Tai Wai and Tuen Mun. Within just one year, uSMART Securities has expanded its Hong Kong service network to 12 physical service centres, surpassing industry benchmarks and actively implementing its "Online x Offline" (O2O) community finance strategy. This expansion solidifies its position as the “No.1 Hong Kong Funded Fintech Brokerage^” and further enhances brand influence.Promoting Accessible Community Financial ServicesThe Tuen Mun branch held a simple yet meaningful opening ceremony today, marking the official commencement of services and a new chapter in the Company's development. Mr. Neo Lee, Executive Director of uSMART Securities, stated: "The opening of the Tai Wai and Tuen Mun branches represent a crucial strategic move in our commitment to local communities and advancing community-oriented services. We focus not only on network coverage but also on connecting with the community, upholding our 'customer-centric' philosophy. By bridging the gap with residents, we are advancing toward our goal of 'seamless coverage across Hong Kong'."(From left to right: Business Development Manager of uSMART Securities, Executive Director of Research Department of uSMART Securities, Executive Director of uSMART Securities, Marketing Director of uSMART Securities and Business Development Director of uSMART Securities)(From left to right: Business Development Manager of uSMART Securities, Executive Director of Research Department of uSMART Securities, Executive Director of uSMART Securities, Marketing Director of uSMART Securities and Business Development Director of uSMART Securities)Comprehensive Coverage Across Hong Kong 18 DistrictsAiming to accelerate the goal of becoming "the Fintech brokerage with the most service centres in Hong Kong," uSMART Securities will open branches in core areas, Kai Tak and Mong Kok in the second quarter. The company is also actively exploring pop-up stores in shopping malls and participating in various exhibition booths. Through multi-channel engagement with customers across different districts, the company aims to refine its regional presence, enabling citizens across all 18 districts to easily access professional and personalized investment and wealth management services, seamlessly integrating financial experiences into daily life.Diversified Investment ProductsAt the opening ceremony, Neo revealed that uSMART Securities has recently obtained a futures trading license and is preparing to launch futures trading services by mid-year. Upon launch, clients will be able to trade futures, including index futures, commodity futures, and currency futures via the uSMART platform. This expansion provides investors with a more comprehensive range of investment products covering long-term, medium-term, and short-term investments, as well as low, medium, and high expected returns, catering to diverse client needs.Futures services will be fully integrated into the existing uSMART APP trading platform, allowing clients to trade US and Hong Kong stocks, futures, ETFs, funds, and discretionary investment products from a single APP. This enables diversified asset allocation, risk management, and wealth enhancement services, allowing clients to utilize capital efficiently and manage investment portfolios flexibly, truly achieving "one-stop wealth management with comprehensive asset allocation."Promoting Investment Education and Enhancing Client InteractionuSMART Securities is also committed to advancing investor education, regularly hosting various online and offline investment seminars and thematic events such as wine tastings and cocktail workshops. These initiatives deepen client engagement and relationships, enhancing customer retention and loyalty.Meanwhile, a new financial channel led by stock commentator and Executive Director of Research, Mr. Dickie Wong, will officially launch next Monday (March 16). Before the market opens and midday close on every Hong Kong stock trading day, a professional team will provide you with real-time analysis of market dynamics and investment opportunity. uSMART Securities aims to foster closer interaction, helping clients refine their practical skills, optimize investment decisions, and build a more comprehensive platform for learning and practice.Expanding Team SizeIn line with rapid business growth, uSMART Securities is actively advancing local talent recruitment and training. The company expects to increase its workforce by 30% over the next two years across areas including branch operations, product design, wealth management, compliance and risk control, and marketing operations. This expansion aims to enhance team scale and professional capabilities, driving steady business growth.Looking ahead, uSMART Securities will continue to optimize trading experiences and strengthen synergies between offline service points and community activities, further solidifying its leading position in financial technology. By combining innovative technology with community networks, the company strives to provide more convenient and personalized wealth management services for investors of all ages and experience levels, promoting the popularization and intelligent development of Hong Kong's financial ecosystem.^”No.1 Hong Kong Funded Fintech Brokerage" is based on TradeGo Cloud data, with uSMART Securities ranking first in monthly transaction volume among local Hong Kong-funded internet brokers for over a year as of February 2026.About uSMART:uSMART Securities is a leading Hong Kong Funded Fintech Brokerage founded in 2018. Over the past eight years, it has pioneered the fusion of technology and finance, offering stocks trading, asset management, and wealth management solutions. Its proprietary platforms, uSMART HK APP and uSMART SG APP, operated by uSMART Securities (Hong Kong) and uSMART Securities (Singapore) respectively. It supports investments in Hong Kong stocks, US stocks, A-shares (via Shanghai and Shenzhen Stock Connect), Singapore Stocks, Japan Stocks, UK Stocks, US options, ETFs, Funds, Bonds, Asset Management, Structured Notes, Futures, Crypto, Precious Metals, Gold, and forex. Furthermore, uSMART is equipped with a highly professional research and asset management team that offers asset management, wealth management, securities brokerage, institutional business, LPF services, and investment banking, dedicated to serving ultra-high-net-worth individuals and families, corporations, investment institutions, fund companies, and other brokerage firms with comprehensive asset management solutions.For details please visit: https://hk.usmartglobal.comFor any media queries, please contact:Carrie Wong9788 4665carriewong@usmart.hk Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SHENZHEN, CHINA, Mar 13, 2026 - (ACN Newswire via SeaPRwire.com) - On 12 March 2026, China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health, which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited) has its innovative prescription medicine ruxolitinib phosphate cream (Lumirix®) (the “Product”, marketed as Opzelura® in the U.S., Europe and Canada) recorded the initial prescriptions for vitiligo patients across 30 provincial-level regions. The prescriptions cover approximately a thousand influential public and private medical institutions in the field of skin health and disease management, including Huashan Hospital, Fudan University, Shanghai Skin Disease Hospital, Dermatology Hospital of Southern Medical University, Second People's Hospital of Chengdu, The First Bethune Hospital of Jilin University, The Second Xiangya Hospital of Central South University, United Family Healthcare Group, among others*. Meanwhile, the Product has become concurrently accessible via over 1,300 offline drugstores as well as JD.com e-commerce platform. *Hospital rankings are listed in no particular order.As the first topical JAK inhibitor approved in China for the treatment of vitiligo, ruxolitinib phosphate cream has officially launched its large-scale clinical application today, marking a breakthrough in China’s vitiligo treatment landscape and ushering in a new era of precision targeted therapy for vitiligo. Supported by safety and efficacy fully demonstrated in clinical studies, the Product is expected to bring new hope for repigmentation to millions of vitiligo patients.The rapid commercialization progress of ruxolitinib phosphate cream underscores strong product operation capabilities of CMS (including Dermavon), while also reflecting the robust supports from China’s regulatory reforms in accelerating patient access to clinically urgently needed innovative drugs. Benefiting from the integrated healthcare ecosystem of the Hainan Free Trade Port and the “Urgently Needed Imported Drugs for Clinical Use” policy, the Product initiated pilot clinical use in August 2023 at Boao Super Hospital within the Boao Lecheng International Medical Tourism Pilot Zone. Pilot usage subsequently expanded to designated medical institutions across the Guangdong–Hong Kong–Macao Greater Bay Area, Beijing-Tianjin region and other regions. In accordance with the relevant regulations of China’s real-world data application pilot project, as well as supported by the Hainan Provincial Medical Products Administration and the Administration of the Boao Lecheng International Medical Tourism Pilot Zone, the Product has accumulated real-world clinical data in China under pilot application, significantly accelerating its clinical, registration and approval timelines. The Product received its Drug Registration Certificate on January 30, 2026 (approval date: January 27, 2026).Following its approval, in less than 1.5 months (including the Chinese New Year holiday), the initial prescriptions for ruxolitinib phosphate cream have been issued across multiple regions and hospitals, reflecting the highly efficient collaboration and concerted efforts among CMS teams, regulatory authorities and business partners. With robust support from the cross-departmental coordination mechanism of the Beijing Daxing Airport Economic Zone Joint Administrative Committee, once import conditions were met, the Product completed customs clearance approval, sampling and related customs procedures within 24 hours, and obtained the drug testing report within 7 working days, representing efficient execution and acceleration for the innovative drugs in China. During this process, the Beijing Municipal Medical Products Administration proactively provided end-to-end policy guidance; the government service center has efficiently completed customs clearance filing; the Beijing Institute for Drug Control has conducted methodological pre-testing to accelerate timelines for innovative drug, and continuous worked during the Chinese Spring Festival; and Daxing Airport Customs provided specialized pre-guidance on declaration and swiftly completed customs review and release. Through parallel workflows and coordinated execution, all parties collectively pressed the “fast-forward button” for the Product’s commercialization, helping this urgently needed innovative therapy reach patients faster.As the Product enters the large-scale clinical application stage, it is expected to further strengthen Dermavon’s comprehensive dermatology solutions and brand value. Building on its leadership in skin health, Dermavon will continue to improve accessibility of ruxolitinib phosphate cream to benefit more vitiligo patients and steadfastly safeguard public skin health through innovation.About VitiligoVitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. The discolored areas usually get bigger with time and the condition could influence skin on any part of the patients’ body. Vitiligo usually affects the appearance of patients, especially on exposed areas such as the face and neck. According to a study that involved over 1,000 diagnosed vitiligo patients, over 45% of patients have facial involvement, and over 20% of patients have neck involvement[1].The obvious presence of white patches may make patients feel that their appearance has been compromised, which in turn materially affects their social life, and is associated with a significantly higher incidence of mental health disorders; accordingly, there is an urgent need for effective treatment options for vitiligo[2].It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million[1]. Existing therapies, such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs), have clinical limitations, with adverse reactions or limited efficacy with long-term use. Ruxolitinib phosphate cream successfully fills the gap in targeted drug treatment for vitiligo and is of great landmark significance.More Information About Ruxolitinib Phosphate CreamRuxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte, is the first and only drug approved for the repigmentation of non-segmental vitiligo by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA)[3,4]. In the U.S., the Product is indicated for the topical treatment of nonsegmental vitiligo in adult and pediatric patients aged 12 years and older, and for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised adult and pediatric patients aged 2 years and older whose disease is not well controlled with topical prescription therapies, or when those therapies are not advisable. In Europe, ruxolitinib phosphate cream is approved for the topical treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. In China, besides vitiligo indication, the product’s NDA for the treatment of mild-to-moderate AD in adults and pediatric patients aged 2 years and older is also under regulatory review, which has been included in the Priority Review List and is expected to accelerate the Product’s AD review process for marketing approval.The Group, through the subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside of Mainland China to the Group (excluding Dermavon and its subsidiary).Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream (excluding territories in which exclusive rights have already been licensed), marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardiovascular-kidney-metabolic/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.Reference:1. China Insights Consultancy’s industrial report 2. Wang G, Qiu D, Yang H, Liu W. The prevalence and odds of depression in patients with vitiligo: a meta-analysis[J]. Journal of the European Academy of Dermatology and Venereology, 2018,32(8):1343-1351. DOI:10.1111/jdv.14739. 3. The U.S. FDA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream4. The EMA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurarCMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsWebsite: https://web.cms.net.cn/en/home/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月13日 - (亚太商讯 via SeaPRwire.com) - uSMART盈立证券有限公司（下称「盈立证券」或「本公司」）欣然宣布，第九及第十间实体服务中心正式进驻大围及屯门，短短一年内，盈立证券全港服务网络已增至12间服务中心，超越全行，积极实践「在线 x 线下」（O2O）小区金融策略，巩固港资科技券商No.1^地位，进一步扩大品牌影响力。推动小区金融服务普及化屯门分行今日举行简单而隆重的开幕典礼，标志该分行正式投入服务，为本公司的发展里程写下崭新一页。盈立证券执行董事李建翰先生 (Neo) 表示：「大围及屯门分行的开业，是我们心系本地小区，持续推动小区化服务的重要战略性部署。我们不仅追求网络覆盖率，更重视与小区的连结，贯彻『以客为本』的理念，拉近与居民的距离，朝『全港无缝覆盖』的目标迈进。」(左起︰盈立证券业务拓展经理林向尊先生、盈立证券研究部执行董事黄德几先生、盈立证券执行董事兼机构业务负责人李建翰先生、盈立证券香港市场部总监黄晓霖小姐及盈立证券业务拓展总监邓永麟先生)(左起︰盈立证券业务拓展经理林向尊先生、盈立证券研究部执行董事黄德几先生、盈立证券执行董事兼机构业务负责人李建翰先生、盈立证券香港市场部总监黄晓霖小姐及盈立证券业务拓展总监邓永麟先生)全港18区服务全覆盖 为加速实现『全港最多服务中心的科技券商』的目标，盈立证券将于第二季在核心地区 ─ 启德及旺角开设分行，并积极物色商场期间限定店及参与各类展会摊位，希望透过多渠道接触不同地区客户，藉此进一步完善地区性布置，让全港18区市民皆可轻松获取专业、个性化的投资理财服务，把金融体验融入日常生活。」投资产品多元化Neo在开幕典礼上透露，盈立证券早前更取得期货交易牌照，并计划于年中正式推出相关业务。届时客户可透过uSMART平台进行期货交易，涵盖指数期货、商品期货及外汇期货等，为投资者提供更全面的投资产品，长、中、短线投资以及低、中、高预期回报俱备，满足不同客户的需求。期货业务将全面整合至现有的 uSMART APP交易平台，客户可使用同一个APP买卖美港股、期货、ETF、基金及全权委托投资产品等，即可享受多元资产配置、风险管理及财富增值服务，高效地运用资金，灵活地管理投资组合，真正实现「一站式理财．全方位布局」。推动投资教育 强化客户互动体验盈立证券对推动投资者教育亦不遗余力，定期举办不同类型的在线及线下的投资讲座，及主题活动，如葡萄酒品鉴会及鸡尾酒工作坊，深化与客户的互动与关系，提升客户黏度，增加客户忠诚度。同时，由资深股评人兼研究部执行董事黄德几先生（Dickie）亲自带领的全新财经台，将于下周一（3月16日）强势启播，每个港股交易日的早上开市及中午收市前，由专业团队为您实时剖析市场动态与投资机遇。盈立证券期望透过更紧密的互动，协助客户精进实战技巧、优化投资决策，打造更完善的学习与实践平台。扩大团队规模 配合业务高速发展，盈立证券正积极推进本地人才招募与培训，预计未来两年职位数量将增加30%，涵盖前线分行、产品设计、财富管理、合规风控及市场营运等范畴，全面扩大团队的规模及专业能力，推动业务稳健成长。 展望未来，盈立证券将持续优化交易体验，并加强线下网点与小区活动的协同效应，进一步巩固在金融科技领域的领先地位；同时结合创新科技与小区网络，为不同年龄及资历的投资者提供更便捷、更具温度的理财服务，推动本地金融生态朝普及化及智能化发展。^「港资科技券商No.1」是取自捷利金融云截至2026年2月为止连续超过一年数据， uSMART盈立证券为香港本地港资互联网券商月成交总额排行第1。关于uSMART盈立证券：盈立证券 是一间领先科技港资券商，成立于2018年，8年来凭借卓越的战略规划和创新能力，致力于将科技与金融深度融合，业务范围涵盖证券、资产管理、财富管理等领域，为全球投资者独家研发了金融证券交易平台 uSMART HK APP和 uSMART SG APP，分别由盈立证券（香港）和盈立证券（新加坡）提供服务。集团APP 支持港股、美股、A股（沪深港通）、新加坡股票、日本股票、英国股票、美股期权、ETF、基金、债券、资管、结构化票据、期货、加密货币、贵金属、黄金和外汇等多元化的投资交易服务，此外更为超高净值个人与家族、企业提供度身订制服务，打造全方位综合性资产管理解决方案。详情可浏览 https://hk.usmartglobal.com传媒查询：黄晓霖 Carrie Wong9788 4665carriewong@usmart.hk Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

深圳, 2026年3月13日 - (亚太商讯 via SeaPRwire.com) - 2026年3月12日，康哲药业控股有限公司 （"康哲药业"）欣然宣布，旗下德镁医药有限公司（"德镁医药"，专业聚焦皮肤健康的创新型医药企业，正申请于香港联合交易所有限公司主板独立上市），其创新处方药磷酸芦可替尼乳膏（百卢妥(R)）（"产品"，在美国、欧洲及加拿大以Opzelura(R)的名称销售）在全国30个省级行政区为白癜风患者开出首批处方，覆盖包括复旦大学附属华山医院、上海市皮肤病医院、南方医科大学皮肤病医院、成都市第二人民医院、吉林大学白求恩第一医院、中南大学湘雅二医院、和睦家医疗集团等千家在皮肤健康及疾病管理领域具有影响力的公立及私立医疗机构*，并实现超1,300家线下药店以及京东电商平台同步可及。*医院排名不分先后磷酸芦可替尼乳膏为中国批准的首款用于白癜风治疗的外用JAK抑制剂，今日正式拉开产品规模化临床应用的序幕，标志着我国白癜风治疗领域实现突破性进展，迈入精准靶向治疗的全新时代，产品将以经过临床充分验证的安全和有效性，点亮千万白癜风患者复色希望。磷酸芦可替尼乳膏的跨越式商业化进程，不仅彰显了康哲药业卓越的产品运营能力，更充分体现了国家药政改革对临床亟需创新药加速可及的有力支持。受益于海南自贸港医疗健康产业整合性优势，以及 "临床急需进口" 政策，2023年8月，产品率先在海南博鳌乐城国际医疗旅游先行区博鳌超级医院启动临床应用，随后试点应用逐步扩展至粤港澳大湾区、京津等区域指定医疗机构。在我国药品真实世界数据应用试点有关程序，以及海南省药品监督管理局与海南博鳌乐城国际医疗旅游先行区管理局的支持下，产品通过"先行先试"临床应用积累中国真实环境的诊疗数据，大大提速产品临床、注册和获批上市进程，并成功于2026年1月30日取得《药品注册证书》（批准日期2026年1月27日）。获批以来，仅耗时不到1.5个月（含春节假期），磷酸芦可替尼乳膏便实现全国多地、多医院首批处方集中落地，这亦是康哲药业各部门、相关监管部门及合作伙伴高效联动、共同努力的成果。在北京大兴临空区联合管委会跨部门合作机制的有力保障下，产品具备进口条件后24小时内即完成了药品通关审批、药品抽样及海关程序，并于7个工作日内取得药品检验报告，全程跑出了高效务实的"中国创新药加速度"。在此过程中，北京市药监局主动开展商业规模批次政策的全流程指导，政务中心高效完成通关备案；北京市药品检验研究院则通过前置方法学预检验、开辟创新药专项通道，并在春节期间持续作业，全力确保检验进度高效推进；大兴机场海关则提前对药品申报要素进行专项指导，快速完成报关审核和药品放行工作。各方协同、流程并联，合力为磷酸芦可替尼乳膏上市按下"快进键"，助力该临床急需创新药惠及广大患者。随着产品进入规模化临床应用阶段，将进一步强化德镁医药皮肤疾病综合解决方案及品牌价值。德镁医药依托在皮肤健康领域的领先地位，将持续推进磷酸芦可替尼乳膏使更多白癜风患者获益，以创新之力坚定守护民众皮肤健康。关于白癜风白癜风是一种慢性自身免疫性疾病，其特征是皮肤色素脱失，其发病原因为产生色素的细胞即黑素细胞的缺失。脱色区域通常会随着时间的推移而扩大，且该病症可能影响患者身体任何部位的皮肤，影响患者的容貌，尤其是面部、颈部等显眼部位。根据一项对1,000多名已确诊白癜风患者进行的研究，超过45%的患者面部受累，超过20%的患者颈部受累[1]。白色斑块的明显存在可能会让患者认为自身的形象受到损害，进而严重影响其社会活动，精神疾病发病率显著增加，因此白癜风的治疗需求非常迫切[2]。据估算，中国约有1,030万人患有白癜风，其中约820万人患有非节段型白癜风[1]。现有疗法，如外用糖皮质激素（TCS）及外用钙调神经磷酸酶抑制剂（TCIs）存在临床缺陷，长期用药有不良反应或疗效有限。磷酸芦可替尼乳膏成功填补了白癜风靶向药物治疗的空白，具有重大标志性意义。关于磷酸芦可替尼乳膏的更多信息磷酸芦可替尼乳膏（Opzelura(R)）是Incyte开发的选择性JAK1/JAK2抑制剂芦可替尼制成的一种创新型乳膏，是经美国食品药品监督管理局（FDA）及欧洲药品管理局（EMA）批准的首款也是唯一一款用于非节段型白癜风复色的药物[3,4]。在美国，产品获批用于局部治疗成人及12岁及以上儿童患者的非节段型白癜风；及其他外用药控制不佳或不建议使用时，非免疫功能受损的2岁及以上儿童和成人轻中度特应性皮炎的局部短期和非持续性慢性治疗。在欧洲，磷酸芦可替尼乳膏被批准用于局部治疗成人及12岁及以上青少年伴面部受累的非节段型白癜风。在中国，除白癜风适应症外，产品2岁及以上儿童和成人轻中度特应性皮炎（AD）适应症亦处于NDA审评阶段， 且该项NDA已获纳入优先审评品种名单，有望加快产品AD适应症上市审评进程。康哲药业于2022年12月2日，通过德镁医药的附属公司与Incyte就磷酸芦可替尼乳膏订立合作和许可协议（"许可协议"），获得在中国大陆、香港特别行政区、澳门特别行政区、台湾地区及东南亚十一国（"区域"）研发、注册及商业化产品的独家许可权利，以及在区域内生产产品的非独家许可权利。德镁医药的附属公司已将磷酸芦可替尼乳膏除中国大陆外的其他区域的相关权利再许可予康哲药业（不包括德镁医药及其附属公司）。Incyte拥有磷酸芦可替尼乳膏全球开发和商业化权利（已独占许可区域除外），在美国及欧洲以Opzelura(R)的名称销售。Opzelura(R)和Opzelura(R)标识是Incyte的注册商标。关于康哲药业康哲药业是一家链接医药创新与商业化，把控产品全生命周期管理的开放式平台型企业，致力于提供有竞争力的产品和服务，满足尚未满足的医疗需求。康哲药业专注于全球首创（FIC）及同类最优（BIC）的创新产品，并高效推进创新产品临床研究开发和商业化进程，赋能科研成果向诊疗实践的持续转化，造福患者。康哲药业聚焦专科领域，拥有被验证的商业化能力，广泛的渠道覆盖和多疾病领域专家资源，核心在售产品已获领先的学术与市场地位。康哲药业围绕优势专科领域不断纵深发展，以巩固心肾代谢/消化/眼科/皮肤健康业务竞争力，带来专科规模效率，其中皮肤健康业务（德镁医药）已成为其细分领域的龙头企业，并拟于联交所独立上市。同时，康哲药业持续推动研产销全产业链在东南亚及中东区域运营发展，以获取新兴市场的增量，助力集团实现高质量可持续发展。参考文献/资料1.数据来自灼识咨询报告2.Wang G, Qiu D, Yang H, Liu W. The prevalence and odds of depression in patients with vitiligo: a meta-analysis[J]. Journal of the European Academy of Dermatology and Venereology, 2018,32(8):1343-1351. DOI:10.1111/jdv.14739.3.FDA批准信息可在Incyte官网查询，网址：https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream4.EMA批准信息可在Incyte官网查询，网址：https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar康哲药业免责与前瞻性声明本新闻无意向您做任何产品的推广，非广告用途。本新闻不对任何药品和医疗器械和/或适应症作推荐。若您想了解具体疾病诊疗信息，请遵从医生或其他医疗卫生专业人士的意见或指导。医疗卫生专业人士作出的任何与治疗有关的决定应根据患者的具体情况并遵照药品说明书。由康哲药业编制的此新闻不构成购买或认购任何证券的任何要约或邀请，不形成任何合约或任何其他约束性承诺的依据或加以依赖。本新闻由康哲药业根据其认为可靠之资料及数据编制，但康哲药业并无进行任何说明或保证、明述或暗示，或其他表述，对本新闻内容的真实性、准确性、完整性、公平性及合理性不应加以依赖。本新闻中讨论的若干事宜可能包含涉及康哲药业的市场机会及业务前景的陈述，该等陈述分别或统称为前瞻性声明。该等前瞻性声明并非对未来表现的保证，存在已知及未知的风险、不明朗性及难以预知的假设。康哲药业并不采纳本新闻包含的第三方所做的任何前瞻性声明及预测，康哲药业对该等第三方声明及预测不承担责任。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 13, 2026 - (ACN Newswire via SeaPRwire.com) – 12 March 2026, Guoquan Food (Shanghai) Co., Ltd. ("Guoquan" or the "Company"; stock code: 2517.HK), a leading one-stop home meal products brand in China, announced its annual results for the year ended 31 December 2025, which have been reviewed by the Audit Committee of the Board.Adhering to the strategic positioning of "community central kitchen" in 2025, the Company successfully established a holistic instant retail store network through a multi-channel, multi-scenario omni-channel layout and the deep integration of online and offline operating models. The Company continuously delved into consumers' demand, developed and iterated a diverse suite of product portfolios, deepened refined store operation and management, and strengthened the construction of a membership ecosystem, effectively enhancing store operational efficiency and market competitiveness. Concurrently, the Company continued to deepen its industrial layout and promote the integrated closed-loop construction of "production, supply and marketing", achieving stable development throughout the year.For the year ended 31 December 2025, the Company's revenue amounted to RMB7,810.0 million, representing a year-on-year increase of 20.7%. Gross profit reached RMB1,686.6 million, a year-on-year increase of 19.0%. Net profit was RMB453.9 million, a significant year-on-year increase of 88.2%. Core operating profit (adjusted for non-recurring items such as gains or losses on fair value changes on unlisted convertible redeemable preferred shares and donations for fire rescue in Tai Po, Hong Kong) was RMB460.7 million, representing a year-on-year increase of 48.2%. Basic and diluted earnings per share were RMB0.1630, a substantial year-on-year increase of 93.8%.Continuously Strengthening Omni-channel Instant Retail: Offline Expansion and Online Engagement Drive GrowthAs of 31 December 2025, the Company's total number of stores nationwide reached 11,566, a net increase of 1,416 stores from 10,150 as at the end of 2024, covering 31 provinces, autonomous regions and municipalities. In terms of regional store layout, the Company achieved a net increase of 1,004 township-level stores in 2025. Addressing the consumption characteristics and needs of township markets, the Company developed differentiated product structures and store displays, accurately aligning with consumer demands in lower-tier markets and further enhancing township market penetration. Concurrently, the Company continued to deploy smart retail scenarios in mid-to-high-tier markets, completing the intelligent and unmanned transformation and upgrade of over 3,000 retail stores in 2025, achieving synergistic development between lower-tier and mid-to-high-tier markets.To empower franchisees, facilitate their sales growth, and further expand consumer reach while offering a more flexible shopping experience, the Company continuously provides support and guidance to franchisees in core areas such as store operations and business development. Leveraging the Company's Guoquan APP, WeChat mini-program, third-party food delivery platforms and social commerce platforms (such as Douyin), a multi-level online sales network has been established. In 2025, the Company achieved over 9.41 billion impressions on platforms through its multi-level Douyin accounts matrix. Stores generated GMV of RMB1.49 billion via the Douyin channel, representing a year-on-year increase of 75.3%.Membership Ecosystem Continuously Improved; Product Portfolio Enhances in Scenarization and RichnessIn 2025, the operation of the Guoquan membership program yielded significant results, further releasing the value of the membership ecosystem. During the Reporting Period, the number of the Company's registered members reached approximately 64.9 million, a year-on-year increase of 57.1%, demonstrating rapid expansion of the membership base. The prepaid card business also achieved stable growth, with the value stored in prepaid cards amounting to approximately RMB1.2 billion during the Reporting Period, a year-on-year increase of 22.3%. This indicates continuously improving member stickiness and consumption contribution, forging a closer connection with consumers.Relying on its substantial membership base, the Company persistently pursues innovation in its product offerings, consistently upholding the business philosophy of providing consumers with "tasty, convenient and value-for-money" products. It continuously enriches its product portfolio and iterates new products to comprehensively meet consumers' diverse dining needs. As of 31 December 2025, the Company had introduced 282 new SKUs of hot pot and barbecue products. It created multiple scenarized meal suites such as the "Barbecue Camping Container Set", "Crayfish Feast Set", and "Six Popular Hot Pot Sets", achieving deep integration of products and consumption scenarios. Furthermore, the Company expanded its product categories within the drinks and beverage consumption scenario, launching products such as NFC fruit juices, craft beer, and flavored tea beverages. This continuously enhances the richness and diversification of the product matrix, further perfecting the one-stop meal products supply system.Deepening Industrial Layout; Strengthening Digitalized Supply Chain ControlGuoquan continues to promote the integrated closed-loop construction of "production, supply and marketing". Adopting a "one-product-one-factory" strategy, it further deepens the breadth and depth of its industrial layout, providing solid production capacity support for business development. As of 31 December 2025, the Company possessed seven food ingredient production plants, covering core categories such as condiments, meatballs, paste and aquatic products, and beef products, forming a comprehensive and well-defined production capacity matrix. Concurrently, the construction of the Company's food production base in Danzhou, Hainan Province, officially commenced. This base will further expand its geographical coverage, optimize the supply chain's radiation radius, and strengthen the national production capacity layout and logistics reach.This solid industrial foundation continuously improves the operational efficiency of the digitalized supply chain. Based on the supply chain system operating from factory to central warehouse and to retail stores, the Company can monitor supply and demand dynamics from the procurement end to the store end, and closely manage inventory levels, thereby achieving efficient management of the entire supply chain. As of 31 December 2025, the Company had deployed 20 digitalized central warehouses across China, achieving swift product circulation through digital stock and barcode management. Simultaneously, the digitalization of the supply chain covering core segments such as production, procurement, warehousing, and logistics allows for precise monitoring of supply-demand dynamics and inventory levels, ensuring the timely supply of products to stores in the Chinese mainland. This comprehensively enhances the overall operational efficiency of the supply chain, solidifying core barriers in cost control and quality assurance.Six Core Strategic Directions: Continuously Advancing Business UpgradesIn 2026, Guoquan targets that the total number of stores will exceed 14,500, representing a net increase of over 2,934 stores, with an estimated store closure rate of less than 4%. It targets high-single-digit growth in store efficiency, and the number of registered members is targeted to exceed 95 million. The Company targets that the growth rate of core operating profit will be significantly higher than that of its revenue.First, Fully expand the sales network with four stores jointly advancing with concerted efforts. Guoquan will continue to build a multi-level sales network, accelerate the expansion of large stores in townships, practice the philosophy of "food equality", and precisely meet the consumption needs of residents in county and township markets. Concurrently, it will explore innovative store formats and upgrade the franchisee management system to build a symbiotic and mutually beneficial franchise ecosystem.Second, Deepen the strategy of community central kitchen to expand community consumption scenarios. The Company will focus on creating food retail solutions for "four meals a day", continuously diversifying its product categories and building a more competitive product matrix to achieve organic sales growth while further consolidating its advantages in lower-tier market layout.Third, Deepen membership operation and IP to advance the community brand project. The Company will continue to advance refined membership operation, deeply integrate media resources such as popular TV commercials, offline community advertising and social media and e-commerce platforms (such as Douyin) to expand its membership base, and improve the membership rights system to enhance member loyalty and stickiness. Furthermore, it will further deepen the operation of its brand IP image "Guobao" to strengthen brand value and emotional resonance with consumers.Fourth, AI big data empower stores to innovate smart retail scenarios. By integrating Internet of Things, big data, and AI technology, the Company will drive the smart operation of stores with data. It will promote the in-depth integration of the Guoquan stir-fry business format with smart cooking machines, accurately analyze consumers' dining habits, optimize dish parameters and cooking procedures for smart cooking machines, realize the standardized production of stir-fry dishes, and optimize the consumer experience.Fifth, Continue to promote the industrial layout and strengthen the advantage of one-product-one-factory. Adhering to the "one-product-one-factory" strategy, Guoquan will further integrate upstream resources domestically and internationally, accelerate the construction of the food production base in Danzhou, Hainan Province, increase R&D investment, and launch more product portfolios with a high quality-price ratio.Sixth, Develop overseas markets in phases to deliver the good taste of China. Guoquan plans to explore and establish a presence in overseas regional markets in a phased manner to unlock long-term growth potential. Leveraging its core competitiveness, it will steadily advance its overseas market exploration. It also plans to take the lead in opening stores in Hong Kong Special Administrative Region, China to accumulate and gather operational experience, gradually achieving overseas product sales and enhancing global brand visibility.About Guoquan Food (Shanghai) CO., LTD. (2517.HK):Guoquan Food (Shanghai) Co., Ltd. (“Guoquan”; Stock Code: 2517.HK) is the leading one-stop home meal products brand in China, offering a variety of ready-to-eat, ready-to-heat, ready-to-cook and prepared ingredients, with a focus on at-home hotpot and barbecue products. Leveraging Company’s robust supply chain capabilities, a strategic industrial layout with self-owned factories, a nationwide network of around 10,000 instant retail stores, and a carefully curated product portfolio, Company offer a variety of home meal products solution under the “Guoquan Shihui” brand, catering to different dining scenarios.This press release is issued by EverBloom (HK) Communications Consultants Group Limited on behalf of Guoquan Food (Shanghai) Co., Ltd. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

From a joyful Raya musical to new and improved festive recipes, Spritzer Sparkling inspires Malaysians to embrace fresh new ideas alongside tradition to elevate their Raya celebrationsSpritzer Sparkling’s 2026 Raya musical brand film “Samting-Samting”, stars Fimie Don and Wani Kayrie as a married couple, and Elliza Razak as Mak Ngah.TAIPING, Malaysia, Mar 13, 2026 - (ACN Newswire via SeaPRwire.com) - Hari Raya Aidilfitri in the month of Syawal is a cherished time of celebration and time-honoured family traditions, with the kitchen often becoming the heart of the festivities. As families balik kampung and fill their homes with the joy and warmth of festive cooking this year, Spritzer Sparkling invites Malaysians to celebrate Raya with a modern twist through its ‘Serikan Raya, Sparkling-kan Suasana’ campaign, showcasing the versatility of the product in boosting the creativity and flair of beloved Raya dishes.For the first time, Spritzer Sparkling is expanding beyond its well-loved role as a beverage mixer with a fresh take on festive cooking through the multipurpose use of its naturally refreshing sparkling water in your favourite recipes. Spritzer Sparkling transforms five traditional must-have Raya dishes into festive showstoppers, bringing a new dimension of taste with its lively carbonation enhancing the texture, crispiness, and tenderness of the dishes. These favourites include Cucur Udang Crispy, Rendang Tok Melting, and Roti Jala with Kari Ayam, alongside refreshing drinks like Bunga Longan Sparkling and Limau Selasih Pudina Sparkling.This Raya, add a little ‘Samting-Samting’ extra to your recipes for an exciting new twist on your favourite festive dishes with Spritzer SparklingEach recipe showcases how the natural bubbles from Spritzer Sparkling help create lighter, crispier batters for a satisfying crunch and more tender, flavourful meats without changing the essence of the dishes. Whether it is giving your cucur udang a delightful crisp or tenderising your rendang meat and shortening the braising time, Spritzer Sparkling makes these traditional favourites even more enjoyable in simple, effortless ways.Shiao Chan, Head of Marketing at Spritzer, said, “Hari Raya Aidilfitri is a celebration deeply rooted in family traditions where food plays a central role in bringing people together. Through ‘Serikan Raya, Sparkling-kan Suasana’, we wanted to show Malaysians that tradition and heritage can co-exist and even be preserved through innovation and new perspectives. Spritzer Sparkling is not just a refreshing beverage for every season, but also a multi-faceted ingredient that can enhance festive dishes and drinks, creating memorable family moments in the kitchen and around the dining table.”A Musical Aidilfitri AwaitsBringing the Raya story to life is Spritzer’s musical film titled ‘Samting-Samting’, starring Fimie Don, Wani Kayrie and Elliza Razak. As the official Spritzer Sparkling brand ambassadors for Raya 2026, Fimie Don and Wani Kayrie, play a modern newlywed couple returning to the husband’s kampung for their first Raya together in the film that blends comedy, drama and music in an irresistibly Malaysian narrative.The young wife, Alia, takes on the kitchen with confidence, using her own modern approach to classic family dishes, prepared using her secret ingredient: Spritzer Sparkling. Mak Ngah, the family’s long-standing culinary matriarch, feels her role is being challenged and grows increasingly suspicious about Alia’s unusually delicious cooking, suspecting “Samting-Samting” is amiss. The story humorously unravels the “secret” behind Alia’s crowd-pleasing flavours, capturing family dynamics and celebrating new perspectives, shared discovery, and the warmth of intergenerational bonding.Home-cooks excited to try this new twist to classic recipes can check out the recipes for the featured dishes and beverages using Spritzer Sparkling as a game-changing ingredient on Spritzer’s Raya microsite here.Spritzer’s 2026 Raya campaign celebrates family traditions, playful generational dynamics in the kitchen, and creative festive cooking with Spritzer Sparkling.Also available on the website are the musical film, promotional details, meet-and-greet information with Fimie Don and Wani Kayrie, as well as gift-with-purchase promotions available at participating outlets nationwide.About SpritzerEstablished in 1989, Spritzer is a leading Malaysian bottled water brand, sourcing natural mineral water from a protected 430-acre rainforest in Taiping. Naturally filtered through underground rock layers for over 15 years, our water is enriched with essential minerals like Silica, known to support skin, bones, hair, and nails.Combining smart manufacturing with sustainable practices, Spritzer ensures every bottle meets the highest quality and safety standards. Our packaging is 100% recyclable and made from recycled materials, reflecting our commitment to environmental stewardship and a circular economy.Tested annually by SIRIM to be free from microplastics, Spritzer offers consumers trusted, natural hydration. Our diverse product range includes Natural Mineral Water, Original and Flavoured Sparkling Water, Distilled Water, and Fruit-Flavoured Beverages—crafted to suit every lifestyle and occasion.With a clear vision to become a fully circular brand by 2030, Spritzer leads the industry in innovation, quality, and sustainability.Spritzer — where nature, innovation, and sustainability come together in every bottleFor more information, visit www.spritzer.com.myFor media inquiries please contact:Farah ShahrulAssociate Consultant, Narro CommunicationsE: farah@narrocomms.comWinnie ChinHead of Public Relations, Spritzer BhdE: winniecgl@spritzer.com.my Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月13日 - (亚太商讯 via SeaPRwire.com) - 中国领先的一站式在家吃饭餐食产品品牌锅圈食品（上海）股份有限公司（简称"锅圈"或"公司"，股票代号：2517.HK）公布截至2025年12月31日止十二个月经董事会审核委员会审阅之全年业绩。2025年，锅圈坚持"社区央厨"的战略定位，通过多渠道、多场景的全域布局，深度融合线上线下运营模式，成功构建全方位的即时零售门店网络。公司持续深耕消费者需求，不断开发并迭代多样化套餐产品组合，深化门店精细化运营管理，健全会员生态体系建设，有效提升了门店经营效能与市场竞争力。与此同时，公司持续深化产业端布局，推动"产供销"一体化闭环建设，实现全年稳健发展。截至2025年12月31日止年度，锅圈收入为人民币7,810.0百万元，同比增长20.7%；毛利为人民币1,686.6百万元，同比增长19.0%；净利润为人民币453.9百万元，同比增长88.2%；核心经营利润（经调整后非上市可转换可赎回优先股公允价值变动损益、香港大埔火灾救援捐赠等一次性因素后）为人民币460.7百万元，同比增长48.2%；每股基本及摊薄盈利为人民币0.1630元，同比增长93.8%。持续夯实全渠道即时零售 线下扩张+线上联动驱动增长截至2025年12月31日，锅圈全国门店总数达11,566家，较2024年末的10,150家净增1,416家，全面覆盖全国31个省、自治区及直辖市。在门店区域布局上，2025年公司净新增1,004家乡镇门店，并针对乡镇市场消费特点与需求，打造差异化产品结构与门店陈列，实现与下沉市场消费需求的精准匹配，进一步提升乡镇市场渗透率。与此同时，公司持续布局中高线市场智能化零售场景，2025年完成超三千家零售门店的智能化、无人化改造升级，实现下沉市场与中高线市场的协同发展。为赋能加盟商、促进其销售增长，并进一步扩大消费者覆盖范围、提供更灵活的购物体验，公司持续在门店运营、业务发展等核心环节为加盟商提供支持，依托锅圈APP、微信小程序、第三方外卖平台及社交商务平台（如抖音），构建多层次的线上销售网络。2025年，公司通过多层级抖音账号矩阵实现超94.1亿次平台曝光量，门店通过抖音渠道实现GMV达14.9亿元，同比增长75.3%。会员生态体系持续完善 产品矩阵场景化与丰富度双提升2025年，锅圈会员计划运营成效显著，会员生态体系价值进一步释放。于报告期内，公司注册会员数量达约6,490万名，同比增长57.1%，会员规模实现快速扩张；预付卡业务同步实现稳健增长，报告期内预付卡预存金额达约人民币12.0亿元，同比上升22.3%，会员黏性与消费贡献持续提升，与消费者的连结更为紧密。以庞大的会员基础为依托，公司持续深耕产品端创新，始终秉持"好吃方便还不贵"的经营理念，不断丰富产品组合并迭代新品，全方位满足消费者多样化用餐需求。截至2025年12月31日，公司共推出282个火锅及烧烤类产品的新SKU，打造"烧烤露营集装箱套餐""小龙虾畅享套餐""六大国民火锅套餐"等多款场景化套餐产品，实现产品与消费场景的深度融合。此外，公司围绕酒水饮料消费场景进行品类拓展，推出NFC果汁、精酿啤酒、风味茶饮等产品，持续提升产品矩阵的丰富度与多元化程度，进一步完善一站式餐食产品供给体系。深化产业端布局 强化供应链数字化管控锅圈持续推动"产供销"一体化闭环建设，通过"单品单厂"策略进一步深化产业端布局的深度与广度，为业务发展提供坚实的产能支撑。截至2025年12月31日，公司已拥有7个食材生产厂，覆盖调味料、丸滑水产、牛肉等核心品类，形成品类齐全、分工明确的产能矩阵；与此同时，公司位于海南省儋州市的食品生产基地正式动工建设，未来将进一步拓宽地理覆盖范围，优化供应链辐射半径，强化全国产能布局与物流辐射能力。产业端的坚实基础推动供应链数字化运营效率持续提升，基于从工厂到中央仓再到零售门店的供应链体系，公司能对从采购端到门店端的供需动态进行监控，并密切把控存货水平，从而实现对整个供应链的高效管理。截至2025年12月31日，公司已布局20个数字化中央仓库，透过数字化存货和条码管理实现产品快速流通；与此同时，实现生产、采购、仓储、物流等核心环节的供应链数字化，精准监控供需动态与存货水平，保障中国内地门店产品及时供应，全面提升供应链整体运营效率，筑牢成本管控与品质把控的核心壁垒。六大核心战略方向 持续推进业务升级2026年，锅圈预计门店总数超过14,500家，即净新增门店超2,934家，预计关店率低于4%，门店店效实现高单位数增长，注册会员数量超过95百万名。公司预计核心经营利润增速将明显高于收入增速。一是，全面拓展销售网络，四店齐发聚力共进。锅圈将继续打造多层级销售网络，加速乡镇大店拓展步伐，践行"美食平权"理念，精准对接县乡市场居民的消费需求；与此同时，探索创新店型且升级加盟商管理体系，构建共生共赢的加盟生态。二是，深化社区央厨战略，延展社区消费场景。公司将围绕"一日四餐"打造餐饮零售解决方案，持续布局多元品类，打造更具市场竞争力的产品矩阵，实现销售规模的有机增长的同时，进一步夯实下沉市场布局优势。三是，深耕会员运营及IP，推进社区品牌工程。公司将持续推进会员精细化运营，深度整合知名电视广告、线下社区广告和社交电商平台（如抖音）等媒体资源，扩大会员规模，并完善会员权益体系，提升会员忠诚度与黏性。与此同时，公司将进一步深化品牌IP形象"锅宝"的运营，提升品牌价值与消费者的情感连结。四是，AI大数据赋能门店，创新智慧零售场景。结合物联网、大数据及AI技术实现门店智能化运营，推动锅圈小炒与智能炒菜机深度融合，精准分析消费者餐饮习惯，优化智能炒菜机的菜品参数与烹饪流程，实现菜品标准化制作并优化消费体验。五是，持续推动产业布局，强化单品单厂优势。锅圈坚守"单品单厂"策略，将进一步整合海内外上游资源，加快海南省儋州市食品生产基地建设，加大研发投入并推出更多高性价比产品组合。六是，海外市场分阶落地，传递中国好味道。锅圈计划分阶段布局海外市场，挖掘长期增长潜力，立足核心竞争力稳步推进海外市场探索，亦计划率先在中国香港开设门店并积累运营经验，逐步实现产品海外销售，提升全球品牌知名度。關於鍋圈食品（上海）股份有限公司(2517.HK)：鍋圈食品（上海）股份有限公司（股票代號：2517.HK）是中國領先的一站式在家吃飯餐食產品品牌，提供即食、即熱、即煮和即配食材，並專注於在家火鍋和燒烤產品。憑藉強大的供應鏈能力、自有工廠的產業端佈局，遍佈全國的萬家即时零售門店網絡及精心策劃的產品組合，公司使用「鍋圈食匯」品牌為消費者提供各種在家吃飯餐食產品解决方案，服務於不同的用餐場景。本新聞稿由九富（香港）財訊公關集團有限公司代表鍋圈發佈。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - March 12, 2026) - Founders Metals Inc. (TSXV: FDR) (OTCQX: FDMIF) (FSE: 9DL0) ("Founders" or the "Company") announces that Lower Antino has been upgraded from Intermediate to Advanced Target status - the same internal classification* as Upper Antino - at its Antino Gold Project in southeastern Suriname (Figure 1). The upgrade follows cumulative drilling of 50 diamond drill holes including eight new holes reported here that continue to demonstrate broad, continuous gold mineralization, highlighted by 65.9 metres (m) of 1.16 grams per tonne (g/t) gold (Au) within a broader envelope of 115.0 m of 0.83 g/t Au from surface in drill hole LA046.HighlightsLower Antino upgraded to Advanced Target status with 50 drill holes released to date with an additional 10 holes pending assays and further expansion drilling underwayBest intercept to date: 65.9 m of 1.16 g/t Au within 115.0 m of 0.83 g/t Au from surface (LA046)Broad mineralized envelopes confirmed: 113.5 m of 0.34 g/t Au from surface including 30.0 m of 0.82 g/t Au (LA044)Intrusion-hosted gold mineralization intersected in all eight drill holes reported in this release; mineralization remains open along strike and at depthColin Padget, President & CEO, commented, "Lower Antino's upgrade from Intermediate to an Advanced Target - now sharing the same classification as Upper Antino - reflects consistent, broad gold mineralization across a growing number of drill holes. LA046 returning 65.9 metres of 1.16 g/t gold within a 115-metre mineralized envelope is the best intercept to date at this target and underscores the scale and continuity of the Lower Antino intrusion-hosted gold system. With gold in every hole and consistently wide intercepts, Lower Antino is emerging as a meaningful contributor to the district's overall potential. While our focus remains on exploration and expansion drilling, Lower Antino's advancement to the same classification as Upper Antino means it is expected to be considered for inclusion in any future resource estimate for the district."Lower Antino - Upgraded to Advanced TargetThe Company reports assay results from eight diamond drill holes (LA043 to LA050) at the Lower Antino target, located approximately 3.5 km east of the Upper Antino deposit (Figure 1). All eight holes intersected gold mineralization, with results highlighted by 65.9 m of 1.16 g/t Au within 115.0 m of 0.83 g/t Au in LA046 (Table 1). The 115-metre intercept in LA046 begins at surface and represents an up-dip expansion of the previously released 90.0 m of 1.02 g/t Au in LA041, confirming the continuity and growth potential of the mineralized zone.Based on cumulative drilling results, Founders has upgraded Lower Antino from Intermediate Target to Advanced Target status, ranking it on the same tier as Upper Antino in terms of overall target quality and scale potential. The upgrade reflects the demonstrated continuity of gold mineralization across numerous drill sections and identification of multiple parallel, northeast-trending mineralized zones over approximately 1.9 km of drill-defined strike length within a broader 1.5 km by 2.8 km gold-in-auger anomaly.The target is open along strike and at depth with drilling ongoing to the south and southeast at regular 100 to 200 metre steps. Overall, gold mineralization remains consistent with previous Lower Antino drill results and is hosted in intensely sericite-altered, sheared tonalite with disseminated pyrite and quartz-pyrite veining. The southernmost hole in this release (LA050), intersected 24.0 m of 0.57 g/t Au and represents approximately 200 metres of southward expansion of the mineralized system. Assay results are presented in Table 1, with drill hole locations in Table 2.Lower Antino is one of two Advanced Targets within Founders' 102,360-hectare contiguous land package, which hosts eight drill tested gold targets across the 55 km long Antino concession. The upgrade of Lower Antino adds meaningful scale to the Company's growing inventory of drill-defined gold mineralization at the district level. The Company will continue to systematically advance and upgrade high-quality targets as defined by geological criteria linked to scale and growth potential.*The Company's internal target classification system reflects drill density, demonstrated continuity of mineralization, and data sufficiency; it does not correspond to NI 43-101 resource categories.Figure 1: Antino Gold Project Property MapTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/7574/288304_571962fb64ca9a3d_001full.jpgFigure 2: Lower Antino Plan MapTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/7574/288304_571962fb64ca9a3d_002full.jpgFigure 3: Lower Antino cross-section through central gold trend.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/7574/288304_571962fb64ca9a3d_003full.jpgTable 1: Lower Antino Drill ResultsDrillholeFrom (m)To (m)Interval (m)Au (g/t)Results from This ReleaseLA043162.00174.0012.001.56incl.167.00174.007.002.56LA0441.50115.00113.500.34incl.8.1038.1030.000.82LA0450.0020.1020.100.31and111.00124.0013.000.44LA0460.00115.00115.000.83incl.41.10107.0065.901.16LA0470.008.108.100.94and149.00156.007.000.46LA0480.0027.6027.600.22and173.00178.005.000.80LA0496.6011.104.500.21LA05047.1071.1024.000.57Previously Released Highlight ResultsLA041156.00246.0090.001.02incl.176.00178.002.0028.44LA00374.10156.0081.901.00incl.106.00132.0026.002.36LA0250.00241.00241.000.27incl.0.0086.1086.100.43LA03329.1060.0030.901.56LA02472.00122.0050.001.02LA028108.00163.0055.000.64incl.110.00117.007.002.32LA0190.0065.0065.000.49incl.44.1065.0020.901.11LA01033.6057.6024.001.23 **Intervals are down-hole depths. True widths of mineralization are estimated to be approximately 85% of the down-hole interval based on currently available results and observations. All are diamond drill holes. Average grades are calculated with un-capped gold assays, as insufficient drilling has been completed to determine capping levels for higher grade gold intercepts. Composites are calculated using a 0.10 g/t Au cut-off grade with

Results Highlights:Revenue increased by 10.0% year-on-year to a record high of US$180.5 million, marking the fifth consecutive year of record-setting revenue performance.Sales volume hit a new high of 2.02 million units, representing a year-on-year increase of 16.2%.Gross profit rose by 7.0% to a record of US$122.4 million; profit attributable to owners of the Company rose by 5.5% to US$41.9 million.The Board has proposed a final cash dividend of HK12 cents per share, bringing the total cash dividend for the Year to HK27 cents per share alongside special dividend, representing a payout ratio of 68.4%.The Group remains in a robust financial position, with cash and bank balances of US$228.7 million at the end of the year for supporting potential acquisitions and the construction of new production facilities.Maintained revenue growth in major markets, with the Asia-Pacific market at 15.7%, the EMEA markets at 19.6%, and the US market at 37.0%.The Group actively leverages its sales network and expertise to assist high-quality medical device peers in selling their products globally, while diversifying its own product portfolio. One of the collaborative products has already been launched in Hong Kong, Malaysia, Germany, and Spain, and is progressively being rolled out to more markets in the APAC and EMEA regions.HONG KONG, Mar 12, 2026 - (ACN Newswire via SeaPRwire.com) – OrbusNeich Medical Group Holdings Limited (“OrbusNeich” or the “Group”; stock code: 6929), a multinational medical device company specializing in interventional devices for percutaneous coronary intervention (“PCI”) and percutaneous transluminal angioplasty (“PTA”) procedures, today announced its annual results for the year ended December 31, 2025 (“FY2025” or the “Year”). Despite significant external challenges, the Group demonstrated remarkable resilience, achieving historic highs in revenue, sales volume, and gross profit, along with improved net profit.During the Year, OrbusNeich’s investments to strengthen its global sales and marketing capabilities, as well as expand product offerings, continued to yield positive results. The Group achieved revenue growth for the fifth consecutive year, reaching a record high of US$180.5 million. Additionally, sales volume in FY2025 hit a new high of 2.02 million units, representing a year-on-year growth of 16.2%, which included an increase of 13.1% from proprietary products and 34.9% from third-party products. Gross profit, up by 7.0% year-on-year, reached a record high of approximately US$122.4 million, with profit attributable to owners of the Company increasing by 5.5% to $41.9 million, and basic earnings per share rising by 5.8% to US5.09 cents.As at December 31, 2025, the Group maintained a strong financial position with cash and bank balances amounting to US$228.7 million. Taking into consideration OrbusNeich’s solid operating performance, healthy cash reserves and future capital requirements, the Board has proposed a final cash dividend of HK12 cents per share (2024: HK10 cents per share), up by 20% year-on-year. Alongside the special cash dividend of HK15 cents per share paid during the Year to celebrate OrbusNeich’s 25th anniversary and express gratitude for shareholders’ long-standing support, the total cash dividend for FY2025 will be HK27 cents per share.Mr. David Chien, Chairman, Executive Director and Chief Executive Officer of OrbusNeich, said, “Building on 25 years of expertise, OrbusNeich achieved another strong performance in FY2025. Our commitment to product innovation and quality, and the establishment of dedicated local teams in diverse markets ensures that our products benefit vascular disease patients worldwide. During the Year, the Group advanced its strategy of building a comprehensive sales network while forging strategic collaborations, including providing commercialization support for Chinese medical device companies expanding overseas. Meanwhile, construction of our R&D and manufacturing base in Hangzhou is progressing steadily, reflecting our long-term growth ambitions.”Extensive Global Sales Network Fuels Strong Multi-Regional Revenue and Business GrowthOrbusNeich maintains an extensive sales network covering over 70 countries and regions through its 12 direct sales teams and distributor network, which includes the acquisition of a Taiwan-based distributor during the Year. During FY2025, the APAC region experienced a significant year-on-year increase in revenue of 15.7%, climbing to US$60.5 million, driven by strong performance in existing direct sales markets and the addition of the Taiwan market. Revenue growth in the EMEA region accelerated, rising by 19.6% to US$46.9 million, supported by rapid growth of over 20% in direct sales markets such as Germany, France, and Spain, along with substantial growth in distributor markets. As the impact of tariffs eased and product demand remained strong, revenue from the US market grew by 37.0% year-on-year, reaching US$21.2 million. Meanwhile, revenue from the Japan and PRC markets totaled US$32.3 million and US$17.8 million, respectively.In the second half of the year, the Group focused on strengthening its market presence in Europe and established a direct sales team in the Netherlands. The Group is establishing another direct sales team in Belgium in 2026, with the goal of achieving direct sales to local hospitals in both markets within the same year.OrbusNeich’s robust global sales network has attracted various manufacturers to collaborate with the Group on international market expansion. During the Year, the Group strengthened its partnership with SonoScape Medical Corp. by distributing their IVUS products across key APAC and European markets, including direct sales regions like Singapore, Malaysia, France, Germany, Spain, and Switzerland, as well as selected distributor markets in Europe. The IVUS products began generating sales in Hong Kong, Malaysia, Germany, and Spain by the end of FY2025.Strengthening a Diversified Portfolio via Parallel Global Registrations and Clinical TrialsAs at December 31, 2025, OrbusNeich owned more than 220 granted patents and published patent applications in key jurisdictions worldwide, as well as 35 PMDA-approved products, 42 CE-marked products, 20 FDA-cleared or approved products, and 24 NMPA-approved products.During the Year, the Group achieved progress in product registrations and clinical trials, including:Obtained PMDA approvals for Teleport Glide, Scoreflex QUAD, EZGuide LL (Large Lumen), Vascuaid and SIDEPASS, CE Marks for JADE PLUS and Teleport Glide, and NMPA approvals for the GuidingArk guiding catheter and Teleport XT;Submitted applications for FDA approval of Teleport Glide, PMDA approvals of Sapphire ULTRA and Sapphire NC ULTRA, and NMPA approvals of Scoreflex TRIO, Teleport Glide, Sapphire NC 24, Sapphire NC ULTRA, Sapphire ULTRA and JADE PLUS;Completed patient enrollment for the US clinical trial of Sapphire 3, with product registration expected to be submitted to the FDA in the first half of 2026;Completed patient enrolment of clinical registries for eucatech AG’s product eucaLimus and SUPPORT C, while patient enrollment for VITUS is still ongoing, with the goal of renewing CE Marks for these products under MDR by the end of 2027;Developing the proprietary coronary paclitaxel drug-coated balloon, Sapphire PTX, with a clinical trial application expected to be submitted to the PMDA in Q1 2026;Developing the peripheral scoring balloon, JADE Score, with registration applications expected to be submitted to the PMDA and the FDA in 2026.Optimizing Global Production Layout for Sustained Long-Term GrowthThe Group’s facilities in Shenzhen, the PRC; Hoevelaken, the Netherlands; and Weil am Rhein, Germany, achieved a combined annual production capacity of approximately 2.1 million units of balloons and stents as at December 31, 2025. To meet future production needs, construction of OrbusNeich’s largest R&D and manufacturing facility in Hangzhou, the PRC, is underway. Following the topping-out ceremony in the second half of 2025, marking the completion of construction of the main structure, renovation work has been ongoing since the end of 2025. The new facility is expected to commence operation in 2027, adding an annual production capacity of 2.4 million units.Mr. Chien concluded, “Looking ahead to 2026, OrbusNeich will continue leveraging its global platform to navigate ongoing external challenges. With the launch of new proprietary and eucatech AG products, rising third-party product sales, and the shift from distribution model to direct sales in certain markets, we expect steady revenue growth in the future. The Group will also explore potential downstream acquisitions in Europe to further consolidate our brand position. Going forward, we aim to sharpen our commercialization edge, maintain leadership in innovation and quality, and explore new business models to drive growth. Ultimately, these initiatives will reinforce our global competitiveness and further our founder, Mr. Teddy Chien’s vision of ‘benefitting humanity’ by improving patients’ quality of life worldwide.”About OrbusNeich Medical Group Holdings LimitedOrbusNeich is a multinational medical device company specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. Headquartered in Hong Kong, China, our Group sells its products in more than 70 countries and regions worldwide. It is also actively expanding into structural heart disease. With an in-house R&D team boasting over 20 years of product development expertise, our Group has developed world-leading proprietary technologies.For more information, please visit the Group’s official website: https://orbusneich.com/.Media InquiriesStrategic Financial Relations LimitedAngelus LauTel: (852) 2864 4805Email: angelus.lau@sprg.com.hkDoris HoTel: (852) 2114 4916Email: doris.ho@sprg.com.hkBailey ZhouTel: (852) 2114 2825Email: bailey.zhou@sprg.com.hkWebsite: https://www.sprg.com.hk/OrbusNeich Medical Group Holdings Limited Maggie LauTel: (852) 3109 7234Email: mlau@orbusneich.comLucille Tsang Tel: (852) 3109 7292Email: ltsang@orbusneich.comWebsite: https://orbusneich.com/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

业绩亮点：收入同比增长10.0%至1.80亿美元，连续五年创新高。销量破纪录，达202万件，同比增长16.2%。毛利上升7.0％至1.22亿美元新高；公司拥有人应占利润增长5.5%至约4,190万美元。董事会建议派发末期股息每股12港仙，连同特别股息，本年度现金股息总额达每股27港仙，派息比率为68.4％。财务状况稳健，年末现金及银行结余为约2.29亿美元，支持潜在收购及新生产设施建设。主要市场收入继续增长，亚太地区市场增长15.7％，欧洲、中东及非洲市场增长19.6%，及美国市场增长37.0%。集团积极透过其销售网络及专业知识，协助优质医疗器械同业的产品迈向全球，同时丰富自身的产品组合。其中一款合作产品已于香港、马来西亚、德国及西班牙上市，并正逐步推广至亚太及欧洲、中东及非洲地区更多市场。香港, 2026年3月12日 - (亚太商讯 via SeaPRwire.com) - 专营经皮冠状动脉介入治疗（PCI）及经皮腔内血管成形术（PTA）手术介入器械的全球医疗器械制造公司业聚医疗集团控股有限公司（"业聚医疗"或"集团"；股份代号：6929）今天宣布截至2025年12月31日止年度（"2025财政年度"或"回顾年"）的全年业绩。尽管外围环境充满挑战，集团仍展现非凡韧性，收入、销量及毛利齐创历史新高，纯利亦录得增长。回顾年内，业聚医疗在强化全球销售与营销能力及扩大产品组合投资方面，继续取得显著成效。集团收入连续五年实现增长，达180.5百万美元新高。2025财政年度销量亦创新高，同比增长16.2%至202万件，其中自有产品及第三方产品销量分别增长13.1%及34.9%。毛利同比增长7.0％至122.4百万美元，同创历史高位；公司拥有人应占利润增长5.5%至41.9百万美元。每股基本盈利上升5.8%至5.09美仙。于2025年12月31日，集团的财务状况维持稳健，现金及银行结余达约228.7百万美元。鉴于业聚医疗稳健的营运表现、充裕的现金储备及考虑到未来资本需求，董事会建议派发末期现金股息每股12港仙（2024年：每股10港仙）。连同较早前为庆祝业聚医疗成立25周年及答谢股东长期支持而派发的每股15港仙特别现金股息，2025财政年度的现金股息总额为每股27港仙。业聚医疗董事长、执行董事兼首席执行官钱永勋先生表示："业聚医疗凭借过去25载建立的实力，于2025财政年度再创佳绩。我们一直坚持产品创新与品质至上的承诺，并建立专业团队扎根全球各主要市场，确保产品可惠及世界各地的血管疾病患者。本年度，集团持续扩展全球销售网络，同时推进多项策略性合作，包括为期望进军海外市场的中国医疗器械企业提供商业化支持。同时，我们位于杭州的研发及生产基地建设进展顺利，充分展现集团寻求长远增长的决心。"销售网络遍及全球，推动多区域收入及业务强劲增长业聚医疗的庞大销售网络，是由12个直销团队（包括本年度收购的一家台湾分销商）及分销商网络组成，遍及全球70多个国家和地区。2025财政年度，有赖现有直销市场的强劲表现及台湾市场的额外贡献，亚太地区收入同比大幅增长15.7%至60.5百万美元；欧洲、中东及非洲地区方面，德国、法国及西班牙等直销市场录得逾20.0%的快速增长，分销商市场亦增长显著，带动该区整体收入加速增长，上升19.6%至46.9百万美元。而随关税影响缓解加上产品需求持续强劲，美国市场收入同比增长37.0%至21.2百万美元。而日本及中国内地市场的收入分别为32.3及17.8百万美元。下半年，集团重点强化欧洲市场布局，在荷兰建立了直销团队。2026年，集团正于比利时设立另一直销团队，以期在同年于两地市场实现向医院直销。业聚医疗广泛的全球销售网络吸引了众多制造商携手合作，共同拓展国际市场。本年度，集团深化与深圳开立生物医疗科技股份有限公司的合作，于多个亚太及欧洲主要市场分销其血管内超声（IVUS）产品，涵盖新加坡、马来西亚、法国、德国、西班牙、瑞士等直销市场，以及欧洲数个选定的分销市场。于2025财政年底前，该产品已于香港、马来西亚、德国及西班牙市场实现销售。全球注册与临床齐头并进，强化多元创新产品组合截至2025年12月31日，业聚医疗在全球主要司法管辖区拥有超过220项授权专利及已公布专利申请，包括35款获PMDA批准产品、42款获CE标志产品、20款获FDA许可产品及24款获国家药监局批准产品。本年度，集团在产品注册及临床试验方面继续取得进展，包括：Teleport Glide、Scoreflex QUAD、EZGuide LL（大管腔）、Vascuaid及SIDEPASS获PMDA批准，JADE PLUS及Teleport Glide获CE标志，GuidingArk导引导管及Teleport XT获国家药监局批准；就Teleport Glide向FDA提交检准申请、就Sapphire ULTRA及Sapphire NC ULTRA向PMDA提交批准申请；就Scoreflex TRIO、Teleport Glide、Sapphire NC 24、Sapphire NC ULTRA、Sapphire ULTRA及JADE PLUS向国家药监局提交批准申请；完成Sapphire 3美国临床试验的病人入组工作，预计于2026年上半年向FDA提交产品注册申请；完成eucatech AG旗下产品eucaLimus及SUPPORT C的临床登记的病人入组，并进行VITUS的病人入组工作，目标于2027年底前取得MDR下的CE标志认证；开发自有冠状动脉紫杉醇药物涂层球囊Sapphire PTX，预计于2026年第一季向PMDA提交临床试验申请；开发外周刻痕球囊JADE Score，预计于2026年向PMDA及FDA提交注册申请。优化全球产能布局，实现可持续的长远增长集团位于中国深圳、荷兰荷佛拉肯及德国莱茵河畔魏尔的生产设施，于2025年12月31日的球囊及支架年产能达约210万件。为满足未来生产需要，集团正于中国杭州兴建旗下最大型的研发及生产设施。项目封顶仪式已于2025年下半年举行，标志该设施主体结构工程竣工，装修工程亦于2025年底启动。新设施预计于2027年投入营运，届时将新增年产能240万件。钱先生总结："展望2026年，业聚医疗将继续善用全球平台应对当前外围挑战。随着自有新产品及eucatech AG产品推出、第三方产品销量持续增长，以及部分市场由分销转向直销模式，我们预期未来收入将稳步上升。集团亦将于欧洲物色潜在的下游收购目标，以进一步巩固品牌地位。未来，我们将继续强化商业化方面的竞争优势，保持产品创新与卓越品质方面的领先地位，并积极探索新业务发展模式，以达致增长。这些举措不仅能巩固集团的全球竞争力，更将延续创始人钱学雄先生‘造福人群’的初心与使命，为全球患者带来更美好的生活。"关于业聚医疗集团控股有限公司业聚医疗是一家全球医疗器械制造公司，专门生产用于经皮冠状动脉介入治疗（PCI）及经皮腔内血管成形术（PTA）的介入器械。本集团总部位于中国香港，产品销往全球超过70个国家和地区。集团亦积极将业务扩展至结构性心脏病领域。凭借拥有逾20年产品开发经验的内部研发团队，本集团已开发出世界领先的专有技术。如需了解详情，请访问集团官网：https://orbusneich.com/传媒垂询纵横财经公关顾问有限公司刘若琪电话：(852) 2864 4805电邮：angelus.lau@sprg.com.hk 何田田电话：(852) 2114 4916电邮：doris.ho@sprg.com.hk周百霖电话：(852) 2114 2825电邮：bailey.zhou@sprg.com.hk 网站: www.sprg.com.hk业聚医疗集团控股有限公司刘慧菁电话：(852) 3109 7234电邮：mlau@orbusneich.com曾 璐电话：(852) 3109 7292电邮：ltsang@orbusneich.com网站: https://orbusneich.com/ Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com